BTT 105
Alternative Names: BTT-105Latest Information Update: 25 Feb 2022
At a glance
- Originator Biotoxtech Co
- Developer Biotoxtech Co; Hanyang University
- Class Antifibrotics; Hydroquinones
- Mechanism of Action Lipid peroxidation inhibitors; NF-E2-related factor 2 stimulants; Nitric oxide synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic fatty liver disease